FIGURE 2.

Individual participant dynamics of total hepatitis B surface antigen (T‐HBsAg), medium HBsAg (M‐HBsAg), and large HBsAg (L‐HBsAg) isoforms during therapy and follow‐up in the REP 301/301‐LTF studies. (A,B) Participants are grouped according to strong HBsAg decline (A) or more moderate HBsAg decline (B). Dashed boxes in (A) highlight the isoform composition at the end of REP 3139‐Ca monotherapy. The 2 participants with moderate quantitative HBsAg (qHBsAg) response, in whom clearance of L‐HBsAg appeared more efficient (001‐09 and 001‐22), are highlighted in bold in (B). The qHBsAg data were previously published.^{[ 33} , ^{41 ]} LLOQ, lower limit of quantitation